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In this double blind, unicentre, randomized, placebo controlled study, we evaluated the changes in 25-hydroxyvitamin D
(25(OH)D) serum levels in 150 young Belgian adults (18–30 years), monthly supplemented with 50,000 IU of vitamin D (VTD)
or placebo for 6 months, from November 2010 to May 2011. At T0, 30% of the population presented 25(OH)D serum levels below
20 ng/mL. In the VTD-treated group, mean serum levels increased from 21.2 ± 8.2 to 30.6 ± 8.8 ng/mL (𝑃 < 0.001) at T3mo and to
36.0 ± 9.2 ng/mL (𝑃 < 0.001) at T6mo. Despite documented VTD intake, no changes in serum levels were, however, observed in
10% of the treated group. In the placebo group, mean 25(OH)D serum levels decreased from 22.8 ± 8.5 to 14.0 ± 6.9 ng/mL at T3mo
(𝑃 < 0.001) but returned to values not significantly different from those observed at T0 (23.5 ± 8.6 ng/mL) at T6mo. No difference
between serum calcium levels was observed between the groups throughout the study. In conclusion, monthly supplementation
with 50,000UI ofVTD inwinter canwarrant serum25(OH)D levels above 20 ng/mL in 96.2%of those healthy young adults without
inducing unacceptably high 25(OH)D concentration.This supplementation is safe and may be proposed without 25(OH)D testing.
1. Introduction
Vitamin D (VTD) deficiency is a worldwide problem [1, 2]. If
all experts agree now to rely on serum 25-hydroxyvitamin D
(25(OH)D) levels to estimate the VTD status, the 25(OH)D
concentration defining VTD sufficiency is still a matter of
debate, with recommendations that can significantly differ
according to the experts. Indeed a recent report by the
Institute ofMedicine (IOM) indicates that a 25(OH)D level of
20 ng/mL is largely sufficient and the recommended dietary
intake (RDIs) set forth (600 IU per day) should be sufficient
for 97.5% of the population to achieve that level [3]. On the
other hand, the Endocrine Society group considers that VTD
deficiency corresponds to 25(OH)D levels of <20 ng/mL
and insufficiency to levels of 20–30 ng/mL suggesting that
higher intake than those recommended by the IOM is
necessary to obtain an optimal VTD status [4]. If severe
vitamin D deficiency, characterized by rickets in children
and osteomalacia in adults, is a rare condition in devel-
oped countries, subclinical VTD deficiency/insufficiency is
extremely frequent and can lead to parathyroid hormone
(PTH) hypersecretion contributing to the development of
osteoporosis in older adults [1]. Vitamin D deficiency is also
associated with an increased risk of falls and fractures in the
elderly [5, 6] and with potential “nonskeletal” effects, notably
on the cardiovascular [7–9] and immune [10] systems as
well as in cancers [11, 12]. Dietary sources of VTD are very
limited and usual daily intakes are generally not higher than
200–400 IU in western countries [13–15]. The major source
of VTD comes from UVB light-driven skin photosynthesis
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but, in northern latitudes like in Belgium (around 51∘ North),
the UVB ray will be insufficient to allow the skin synthesis
of VTD during approximately 6 months of the year. A
pharmacological supplementationmay thus be considered, at
least during thewintermonths. In somepatients such as those
with osteoporosis, different supplementation schemes based
on a baseline 25(OH)D measurements have been proposed
with the aim to target a 25(OH)D level of 30 ng/mL or more
[1, 11]. However, as 25(OH)D measurement is costly, it is
suggested by many authors to supplement most patients and
healthy persons without prior vitamin D testing [16]. For
that purpose, one can rely on the recently published rec-
ommendations indicating that an intake of 600–800 IU/day
[3] or 1500–2000 IU/day [4] is adequate. As observance of
a daily supplementation is a critical issue in general, many
doctors and patients prefer intermittent higher vitamin D3
(VTD3) doses given at intervals ranging from one week to
one to four months. However, before proposing a systematic
supplementation scheme with intermittent vitamin D doses
during the “winter” months without prior 25(OH)D mea-
surement, it is highly important to be sure that, with this
scheme of supplementation, potentially toxic 25(OH)D levels
are avoided, even transiently, and that serum calcium (CA)
concentrations remain normal.
As the literature on the prevalence of VTD deficiency
in the population of younger Belgian adults is scarce and as
very few data regarding supplementation in this population
are available, we aimed, in this prospective, randomized,
placebo-controlled study, to measure the impact of a supple-
mentation with 50,000 IU VTD3 per month during winter
on the serum 25(OH)D levels in young (18–30 years) healthy
volunteers. We also verified if that dose was sufficient to
reach the IOM threshold for a healthy population (20 ng/mL),
without any adverse clinical event or reaching levels that are
considered as potentially harmful.
2. Methods
This study is a double blind, placebo controlled, randomized,
comparative, and monocentre trial consisting in a supple-
mentation of young healthy Caucasian volunteers every 4
weeks in winter (November 2010–May 2011), with either
50,000 IU VTD3 or placebo.
In November 2011, after a screening visit of 195 candidates
at the Liege University Hospital, 150 subjects who fulfilled
the inclusion/exclusion criteria were randomly allocated to
one of the treatment groups in a 1 : 1 ratio. They were healthy
young males or females MD students or physical therapy
students aged 18–30 years, with a body mass index between
18 and 30 kg/m2. Subjects having used within the last 30
days any over-the-counter medicinal products or herbal
supplements or within the last 2 months food supplements
containing VTD, those using UV light solarium, or patients
treated with drugs interfering with VTDmetabolism (pheny-
toin, phenobarbital, carbamazepine, glucocorticoids, digi-
talin, calcium, thiazides,. . .) were excluded from the study.
Other exclusion criteria included hyperparathyroidism, past
or current history of granulomatosis and especially sar-
coidosis, urinary lithiasis, renal insufficiency, cardiac dis-
ease, cancer (of whatever origin), history of radiotherapy
or chemotherapy, osteomalacia, human immunodeficiency
virus or tuberculosis infection, acute or chronic alcohol,
or drug abuse/dependence (including but not limited to
cannabis) within 6 months prior to screening.
Study medication consisted in 1mL ampoules containing
each an oily solution of 25,000 IU/mL of cholecalciferol (D-
cure, SMB Laboratories, Belgium). The placebo, also manu-
factured by SMB Laboratories, consisted of 1mL ampoules
containing the same excipient, but without cholecalciferol.
The ampoules containing the placebo or VTD3 had the
same appearance, color, and taste and were prepacked and
consecutively numbered. Patients were allocated to one of the
two groups (VTDor placebo) by one of the investigators (EC)
without any contact with the subjects in order to have groups
that were as much as possible similar in terms of age, hours of
sport practice, and sex. Investigators (EB and MS) in contact
with the volunteers were kept blind to group assignment.
Six vials of study medication were dispensed at inclusion
visit (T0) in November and in the control visit, in February
(T3mo), after 90± 3 days. Two vials were orally absorbed
in front of the investigators at these two visits. Written
instructions to absorb 2 vials at 30 ± 3 days intervals were
given at inclusion and control. An e-mail and a short message
service (SMS)were sent to each participant at days 27, 57, 117,
and 147 to ensure oral intake of the investigational drug
at appropriate time. Compliance was further verified by
systematic telephone interviews performed by a study nurse,
to confirm the drug intake and register the vials numbers.
Empty vials were returned to the investigator at the next
visit (control visit in February and final visit in May). At
each visit, all potential new complaints and symptoms (i.e.,
those not existing prior to signing informed consent) were
recorded on the Adverse Event Clinical Record Form. Pre-
existing complaints or symptoms that increased in intensity
or frequency after having signed the Informed Consent Form
were also registered as Adverse Events.
The study was approved by the Ethics Committee of the
UniversityHospital of Liege and registered as Eudra-CT2010-
022454-17.
2.1. Laboratory Measurements. Blood samplings were per-
formed in November (T0) before the first 50 000 IU dose was
taken, in February (T3mo) just before the 4th dose, and in
May (T6mo), one month after the 6th dose.
We used the DiaSorin Liaison (Stillwater, MN, USA)
for 25(OH)D and PTH (3rd generation) determination.
Serum calcium was measured with the Roche Modular assay
(reference range: 2.20–2.65mmol/L).
All the samples were kept at −20∘C before determination.
Analyses were performed in batches. In our laboratory,
25(OH)D intra- and interassay coefficients of variation are
<5% and <10%, respectively, and the functional sensitivity
was found to be at 12 ng/mL. The laboratory participates in
the DEQAS proficiency testing and is ISO 15189 accredited
for 25(OH)D and Calcium determinations.
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Table 1: Baseline demographic data of the healthy young Belgian volunteers who agreed to participate in the study. Continuous variables are
expressed as mean ± SD.
Total Placebo group Vitamin D group
SEX:
Male (n) 49 24 25
Female (n) 61 33 28
Age (years) 22.9 ± 2.5 23.0 ± 2.5 22.8 ± 2.6
BMI (kg/m2) 21.8 ± 2.1 21.9 ± 2.2 21.7 ± 2.0
25(OH)D (ng/mL) 22.0 ± 8.3 22.8 ± 8.5 21.2 ± 8.2
% subjects with 25(OH)D >30 ng/mL 12.7 14.0 11.3
% subjects with 25(OH)D between 20 and 30 ng/mL 48.2 49.1 47.2
% subjects with 25(OH)D between 12 and 19 ng/mL 28.2 26.3 30.2
% subjects with 25(OH)D <12 ng/mL 10.9 10.5 11.3
% subjects with 25(OH)D >60 ng/mL 0.9∗ 0 1.9∗
∗One individual.
Table 2: Serum 25(OH)D (ng/mL) levels observed in a young healthy population after 3 and 6 months of supplementation with a monthly
dose of 50,000 IU of cholecalciferol or a placebo. The results are expressed as mean ± SD. A P value <0.05 is considered as significant.
Placebo group Vitamin D group
Baseline (October) 22.8 ± 8.5 21.2 ± 8.2 NS
After 90 days (February) 14.0 ± 6.9 30.6 ± 8.8 𝑃 < 0.0001
After 180 days (May) 23.5 ± 8.6 36.0 ± 9.2 𝑃 < 0.0001
Intragroup comparison
October—February 𝑃 < 0.0001 𝑃 < 0.0001
February—May 𝑃 < 0.0001 𝑃 < 0.0001
October—May NS 𝑃 < 0.0001
2.2. Statistical Analysis. Of the 195 screened volunteers, 150
were randomized and received at least one treatment or
placebo during inclusion visit. One hundred and ten vol-
unteers completed the trial and were included in the per
protocol statistical analysis. Forty individuals were excluded
because of documented major violations of the protocol
(concomitant use of other sources of VTD in 3 instances or
lack of adherence to the protocol in 37 cases (missed visit(s)
or failure to take investigational medication)).
After verifying that the 25(OH)D serum levels presented
a normal distribution, an analysis of variance (ANOVA)
was used for comparison of 25(OH)D levels at the different
visits (November: inclusion; February: control, andMay: final
visit), in each group. A nonpaired student t-test was used
for inter-groups comparison. Adverse events recording was
obtained by questioning and examining subject at control and
final visits.
3. Results
Baseline demographics and serum 25(OH)D levels are pre-
sented in Table 1.
No significant differences were observed at baseline
between the groups.
In November, 13% of this young Belgian population
presented 25(OH)D levels above 30 ng/mL, approximately
half of them had levels comprised between 20 and 30 ng/mL,
while about 40% had values below 20 ng/mL (and 11% even
<12 ng/mL). One individual presented a 25(OH)D concen-
tration higher than 60 ng/mL (61 ng/mL). This subject was
assigned to the VTD group.
At T3mo and T6mo, the 25(OH)D serum levels dif-
fered significantly between both groups (Table 2). After
a 90-day treatment period (February), the mean serum
levels increased from 21.2± 8.2 ng/mL to 30.6± 8.8 ng/mL
in the VTD-treated group whereas it decreased from
22.8± 8.5 ng/mL to 14.0± 6.9 ng/mL in the placebo group.
After 180 days (in May), the mean 25(OH)D serum lev-
els reached 36.0± 9.2 ng/mL in the treated group while in
the placebo group, mean values of 23.5± 8.6 ng/mL were
recorded.
After 3 months of treatment with 50,000 IU of chole-
calciferol, 8% of the subjects only still presented 25(OH)D
levels <20 ng/mL and this percentage dropped to 4% after 6
months. None of the treated subjects did present 25(OH)D
values that were still <12 ng/mL (Table 3). After the 6-month
treatment, 70% and 96% of the subjects had a 25(OH)D
concentration above 30 ng/mL and 20 ng/mL respectively. In
the placebo group, 84.2% of the healthy volunteers had a
25(OH)Dconcentration<20 ng/mL in February (half of these
subjects having a 25(OH)D <12 ng/mL). InMay, the situation
was very similar with the one observed in November: 33%
presented 25(OH)D levels <20 ng/mL (5% <12 ng/mL) and
16% above 30 ng/mL. (Table 3). The distribution of the
individual levels of 25(OH)D reached in the placebo and
vitamin D is presented in Figure 1. The higher increases were
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Table 3: Percentage of patients whose 25(OH)D levels were found in the <12, 20–30, and >30 ng/mL groups in the vitamin D or placebo
group. One patient presented a 25(OH)D level >60 ng/mL in October and another one in May.
Distribution of 25(OH)D serum levels
In volunteers receiving vitamin D
Monthly doses of 50,000 IU of cholecalciferol In volunteers receiving the placebo
25-OH-Vit D Baseline After 90 days After 180 days Baseline After 90 days After 180 days
<12 ng/mL 11.3% 0% 0% 10.5% 42.1% 5.3%
12–19 ng/mL 30.2% 7.6% 3.8% 26.3% 42.1% 28.1%
20–29 ng/mL 47.2% 50.9% 26.4% 49.1% 12.3% 50.9%



















Placebo groupVitamin D group
Figure 1: Serum 25(OH)D (ng/mL) levels observed in a young healthy population after 3 (February) and 6 (May)months of supplementation
with a monthly dose of 50,000 IU of cholecalciferol or a placebo.
observed in patients presenting the lowest initial 25(OH)D
values, but those who had the higher 25(OH)D levels at
inclusion were also those who had the highest values in May.
In this study, body mass index (BMI) was not associated with
the 25(OH)D increase during treatment with VTD3.
The highest serum 25(OH)D concentration (62 ng/mL)
was observed in May in the treated group in a patient
whose baseline level was 33 ng/mL. The patient (included in
the VTD group) presenting 61 ng/mL at inclusion presented
values at 31 and 57 ng/mL in February and May, respectively.
The CA levels of the VTD and placebo groups were
similar in November (2.43± 0.09 and 2.43± 0.08mmol/L,
resp.) and remained identical at T3mo and T6mo and none of
the patients reported any sign or symptoms that could have
been related with vitamin D intoxication nor presented CA
values above 2.65mmol/L.
Finally, analysis of individual variations of 25(OH)D
levels among the volunteers treated by cholecalciferol showed
that 7 of them (13%) did not respond to the treatment as they
failed to display a progressive increase in serum 25(OH)D
levels despite regular and documented intake of the vitamin
D doses.
4. Discussion
In this double-blind, placebo controlled, randomized trial, we
assessed the impact of amonthly administration of 50,000 IU
of vitaminD3 for 6months on serum levels of 25(OH)D in 110
healthy young Belgian university students aged 18–30 years
during winter months.
Our results show that, in the middle of winter, 88% of
our young and active subjects presented 25(OH)D values
below 20 ng/mL, the threshold defined by the IOM as the
limit of deficiency. If we have already shown the magnitude
of this deficiency in our area in special populations like
pregnant women [17] or elderly men living at home or in
institutions [18], these data also show that the majority of
these young active adults is also concerned by vitamin D
deficiency, at least in winter.This can easily be understood as,
in European countries with latitudes ≥37∘N, photo-activation
of previtamin D is minimal or absent between October and
March and the dietary sources of vitamin D are scarce. In
May, after an exceptional spring (actually, spring 2011 was
the sunniest spring ever recorded in Belgium, with 707.15
hours of sunshine [19]), the distribution of 25(OH)D levels
observed in these young healthy adults returned to the
one observed in November. These low levels are generally
associated with poorer outcomes (cardiovascular diseases,
cancers,. . .) in different studies involving participants of
older ages and only rarely concern adults of younger ages.
However, low values of vitamin D have been associated in
younger people with secondary hyperparathyroidism [15],
respiratory tract infections [20], and multiple sclerosis [21].
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A supplementation of this young population with vitamin
D, at least in wintertime, may thus be of good practice. The
IOM has stated that 600 IU could cover the needs of 97.5%
of the population. In this study, we show that an intake
corresponding to a daily dose of 1,666 IU was efficient to
cover 96.2% of the needs of this young population after
6 months (92.4% after 3 months), a result close to the
IOM expectancies, but with an extra 1,000 IU dose. It seems
difficult to think that a supplementation with 600 IU would
have reached this result in winter in our subjects, even if
we did not test it. Accordingly, the IOM recommendation
of 600 IU may be inadequate, at least in winter, to cover the
needs of 97.5% of the population.
This supplementation with 50,000 IU was safe as we did
not observe any variation in calcium levels between the
two groups. No complaints potentially linked to vitamin
D toxicity have neither been registered by the physician
who supervised the study and saw that patients at the
different visits. The higher value achieved with this protocol
was 62 ng/mL, a value that is far from the concentrations
estimated as toxic (>150 ng/mL) [1] and is below the upper
values observed in subjects living near the Equator and
exposing themselves to the sun all year round [18].
Interestingly, we found that 4 participants did not
respond to vitamin D supplementation as they did not
increase their 25(OH)D levels in May. These patients might
of course have been poorly compliants, even if we registered
their intakes and if they confirmed their good compliance.
They might also suffer from intestinal fat malabsorption,
Crohn disease, or inflammatory bowel disease [22] even if
the prevalence (13%) seems too high. This observation is
interesting because it shows that the response to vitamin D
is individual and can be affected by different reasons.
This study has some limitations, like the rather small
number of patients in each group, its monocentric design or
the only one ethnicity tested. Nevertheless, it was conducted
as a true randomized, placebo controlled trial as only one
investigator, working in the laboratory without any contact
with the patients had access to the results. Moreover, there is
a limited number of studies involving young adults.
In conclusions we have shown here that the prevalence
of vitamin D deficiency was very important in Belgian
young adults in wintertime. A monthly dose of 50,000 IU of
cholecalciferol from November to May was able to increase
the 25(OH)D levels of 96.2% of this population above
20 ng/mL without inducing unacceptably high 25(OH)D
concentration. Such a supplementation scheme was safe and
may be proposed without 25(OH)D testing.
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